Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 601–700 of 1,017
Rho GTPases: Anti- or pro-neoplastic targets?
Zandvakili, I., Lin, Y., Morris, J. C., & Zheng, Y. (2016) · Oncogene · doi:10.1038/onc.2016.473 · Cited by 107
Medulloblastoma: Molecular Classification-Based Personal Therapeutics
Archer, T. C., Mahoney, E. L., & Pomeroy, S. L. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0526-y · Cited by 117
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 106
Bladder Cancer: New Insights into Its Molecular Pathology
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10040100 · Cited by 121
SOS GEFs in health and disease
Baltanás, F. C., Zarich, N., Rojas-Cabañeros, J. M., & Santos, E. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188445 · Cited by 100
The intricacies of NRF2 regulation in cancer
Schmidlin, C. J., Shakya, A., Dodson, M., Chapman, E., & Zhang, D. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.016 · Cited by 99
Zhang, J., Song, Y., Shi, Q., & Fu, L. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0830-0 · Cited by 108
Whole-genome landscape of adult T-cell leukemia/lymphoma
Kogure, Y., Kameda, T., Koya, J., Yoshimitsu, M., Nosaka, K., Yasunaga, J., Imaizumi, Y., Watanabe, M., Saito, Y., Ito, Y., et al. (2021) · Blood · doi:10.1182/blood.2021013568 · Cited by 110
Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome
Venkatesan, S., & Swanton, C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158930 · Cited by 121
JMJD family proteins in cancer and inflammation
Wang, M., Jianxin, X., Hong, W., Chen, S., & Huashan, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01145-1 · Cited by 118
The Case for a Pre-Cancer Genome Atlas (PCGA)
Campbell, J. D., Mazzilli, S. A., Reid, M. E., Dhillon, S. S., Platero, S. J., Beane, J., & Spira, A. E. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0024 · Cited by 103
Misactivation of Hedgehog signaling causes inherited and sporadic cancers
Raleigh, D. R., & Reiter, J. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120850 · Cited by 106
Integrative multi-omics module network inference with lemon-tree
Bonnet, E., Calzone, L., & Michoel, T. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003983 · Cited by 98
Furukawa, T., Sakamoto, H., Takeuchi, S., Ameri, M., Kuboki, Y., Yamamoto, T., Hatori, T., Yamamoto, M., Sugiyama, M., Ohike, N., et al. (2015) · Scientific Reports · doi:10.1038/srep08829 · Cited by 104
Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors
Chen, K., Meric-Bernstam, F., Zhao, H., Zhang, Q., Ezzeddine, N., Tang, L.-Y., Qi, Y., Mao, Y., Chen, T., Chong, Z., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.231100 · Cited by 97
OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers
Wang, T., Ruan, S., Zhao, X., Shi, X., Teng, H., Zhong, J., You, M., Xia, K., Sun, Z., & Mao, F. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1033 · Cited by 98
Characterizing genomic alterations in cancer by complementary functional associations
Kim, J. W., Botvinnik, O. B., Abudayyeh, O., Birger, C., Rosenbluh, J., Shrestha, Y., Abazeed, M. E., Hammerman, P. S., DiCara, D., Konieczkowski, D. J., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3527 · Cited by 96
Self-citationRoper, N., Gao, S., Maity, T. K., Banday, A. R., Zhang, X., Venugopalan, A., Cultraro, C. M., Patidar, R., Sindiri, S., Brown, A.-L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.028 · Cited by 97
“Identification and classification of driver mutations—All identified nonsynonymous mutations were filtered to include only driver genes based on large-scale non-small cell lung cancer sequencing studies (Campbell et al., 2016; Ding et al., 2008; Govindan et al., 2012; Imielinski et al., 2012; Lawrence et al., 2014; Ne…”
BackgroundHe, B., Lang, J., Wang, B., Liu, X., Lu, Q., He, J., Gao, W., Bing, P., Tian, G., & Yang, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00394 · Cited by 110
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
“To our current knowledge, the TP53 tumor suppressor gene is the most frequently mutated gene across human cancer, with somatic mutations detected in 36% of 4742 cancers subjected to whole exome sequencing 21 .”
BackgroundSelf-citationGenetic screens and functional genomics using CRISPR/Cas9 technology
Hartenian, E., & Doench, J. G. (2015) · The FEBS Journal · doi:10.1111/febs.13248 · Cited by 95
A Histologic Basis for the Efficacy of SBRT to the lung
Woody, N. M., Stephans, K. L., Andrews, M., Zhuang, T., Gopal, P., Xia, P., Farver, C. F., Raymond, D. P., Peacock, C. D., Cicenia, J. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.002 · Cited by 100
Efficient Pre-mRNA Cleavage Prevents Replication-Stress-Associated Genome Instability
Teloni, F., Michelena, J., Lezaja, A., Kilic, S., Ambrosi, C. M., Menon, S., Dobrovolná, J., Imhof, R., Janščák, P., Baubec, T., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.036 · Cited by 106
“We then designed a targeted small interfering RNA (siRNA) library covering a class of newly emerging, recurrently mutated cancer genes (Davoli et al., 2013; Lawrence et al., 2014; Nijhawan et al., 2012; Zack et al., 2013), using three individual siRNAs against each target gene (Table S1).”
MethodCell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12520 · Cited by 109
Massively parallel phenotyping of coding variants in cancer with Perturb-seq
Ursu, O., Neal, J. T., Shea, E., Thakore, P. I., Jerby-Arnon, L., Nguyen, L., Dionne, D., Diaz, C., Bauman, J., Mosaad, M. M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01160-7 · Cited by 96
Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus–Host Protein Network
Eckhardt, M., Zhang, W., Gross, A. M., Von Dollen, J., Johnson, J. R., Franks-Skiba, K. E., Swaney, D. L., Johnson, T. L., Jang, G. M., Shah, P. S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1018 · Cited by 95
Bădoiu, S. C., Greabu, M., Miricescu, D., Stănescu-Spînu, I.-I., Ilinca, R., Bălan, D. G., Balcangiu‐Stroescu, A.-E., Mihai, D. A., Văcăroiu, I. A., Ștefani, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098391 · Cited by 106
“Lipid phosphatases, such as the tumor suppressor PTEN, quickly break down this compound and stop PI3K signaling by removing the 3 (cid:48) -phosphate [101,102].”
BackgroundCancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma
Guan, J., Gupta, R., & Filipp, F. V. (2015) · Scientific Reports · doi:10.1038/srep07857 · Cited by 94
“In the case of melanoma, however, comprehensive cataloguing of low-frequency mutated genes (in , 2% patients) will require more than 5000 samples 18 .”
InfluentialPharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Homologous recombination deficiency in triple negative breast cancer
Belli, C., Duso, B. A., Ferraro, E., & Curigliano, G. (2019) · The Breast · doi:10.1016/j.breast.2019.02.007 · Cited by 108
Crona, J., Gustavsson, T., Norlén, O., Edfeldt, K., Åkerström, T., Westin, G., Hellman, P., Björklund, P., & Stalberg, P. L. H. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4351-9 · Cited by 100
Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights
Ng, C. K. Y., Schultheis, A. M., Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv015 · Cited by 112
Kim, Y.-A., Cho, D.-Y., Dao, P., & Przytycka, T. M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv247 · Cited by 97
“Despite these strong tissue-specific signals, it has also become evident that many mutated genes, and even whole dysregulated sub-networks, are shared by multiple cancer types (Lawrence et al. , 2014; Leiserson et al. , 2013, 2014).”
BackgroundMembrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers
Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., & Nussinov, R. (2016) · Biochemical Journal · doi:10.1042/bcj20160031 · Cited by 92
Framework to function: mechanosensitive regulators of gene transcription
Finch-Edmondson, M., & Sudol, M. (2016) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-016-0028-7 · Cited by 93
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation
Shankar, G. M., Taylor-Weiner, A. N., Lelic, N., Jones, R. T., Kim, J. C., Francis, J. M., Abedalthagafi, M., Borges, L. F., Coumans, J.-V. C. E., Curry, W. T., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0167-x · Cited by 94
Self-citationAneuploidy in Cancer: Seq-ing Answers to Old Questions
Knouse, K. A., Davoli, T., Elledge, S. J., & Amon, A. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042616-072231 · Cited by 99
“Although the biological basis is unclear, it is consistent with different cancers showing enrichment for different sequence mutations (Kandoth et al. 2013, Lawrence et al. 2014).”
BackgroundDysregulation of the Keap1–Nrf2 pathway in cancer
Leinonen, H. M., Kansanen, E., Pölönen, P., Heinäniemi, M., & Levonen, A.-L. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150048 · Cited by 92
PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis
Chen, Q. Y., & Costa, M. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112268 · Cited by 92
“Many human tumors are associated with loss of phosphatase and tensin homolog function, as well as elevated levels of PIP3, which are now two of the most frequently altered gene functions in human cancers (Lawrence et al., 2014; Fruman et al., 2017).”
BackgroundARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 98
Loss of chromosome Y in primary tumors
Qi, M., Pang, J., Mitsiades, I. R., Lane, A. A., & Rheinbay, E. (2023) · Cell · doi:10.1016/j.cell.2023.06.006 · Cited by 103
Schaefer, M. H., Serrano, L. G., & Andrade-Navarro, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00260 · Cited by 96
“To reconfirm the previously reported (Wachi et al., 2005; Jonsson and Bates, 2006; Rambaldi et al., 2008) difference in the degree distribution between cancer and non-cancer proteins, we retrieved and pooled somatically mutated cancer genes from 21 different tumor types (Lawrence et al., 2014).”
BackgroundMethodThe Role of Somatic L1 Retrotransposition in Human Cancers
Scott, E., & Devine, S. (2017) · Viruses · doi:10.3390/v9060131 · Cited by 91
Wang, L., Sebra, R., Sfakianos, J. P., Allette, K., Wang, W., Yoo, S., Bhardwaj, N., Schadt, E. E., Yao, X., Galsky, M. D., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-0720-0 · Cited by 113
“The list of genes that are significantly mutated in each dataset assessed by Mutsig [17] and the genes that are significantly amplified/deleted estimated by GIST [18] were also downloaded directly from Firehose (206_01_28, Aggregate_AnalysisFeatures).”
MethodHe, B., Dai, C., Lang, J., Bing, P., Tian, G., Wang, B., & Yang, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165916 · Cited by 106
Tóthová, Z., Valton, A.-L., Gorelov, R. A., Vallurupalli, M., Krill-Burger, J. M., Holmes, A. L., Landers, C. C., Haydu, J. E., Małolepsza, E., Hartigan, C. R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.142149 · Cited by 98
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Vo, J. N., Wu, Y., Mishler, J., Hall, S., Mannan, R., Wang, L., Yu, N., Zhou, J. R., Hopkins, A. C., Estill, J. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31430-0 · Cited by 110
Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis
Zhou, W., Liu, H., Yuan, Z., Zundell, J. A., Towers, M., Lin, J., Lombardi, S., Nie, H., Murphy, B., Yang, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.002 · Cited by 109
Su, X., Hu, P., Li, D., Zhao, B.-W., Niu, Z., Herget, T., Yu, P. S., & Hu, L. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01312-5 · Cited by 115
“Comprehensive knowledge of human cancer genes is a critical foundation for exploring the carcinogenesis mechanism of tumour formation 1 .”
Wu, Q., Kroon, P. A., Shao, H., Needs, P. W., & Yang, X. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b02420 · Cited by 92
Zhao, Q., Lei, P., Zhang, X., Zheng, J., Wang, H.-Y., Zhao, J., Li, Y., Ye, M., Li, L., Wei, G., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0201-x · Cited by 100
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
Zhao, Z.-M., Yost, S. E., Hutchinson, K. E., Li, S. M., Yuan, Y., Noorbakhsh, J., Liu, Z., Warden, C., Johnson, R. M., Wu, X., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5290-4 · Cited by 96
Targeting NRF2 to treat cancer
Sivinski, J., Zhang, D. D., & Chapman, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.003 · Cited by 96
Alvarez, M., Benhammou, J. N., Darci-Maher, N., French, S. W., Han, S. B., Sinsheimer, J. S., Agopian, V. G., Pisegna, J. R., & Pajukanta, P. (2022) · Genome Medicine · doi:10.1186/s13073-022-01055-5 · Cited by 101
Standardized decision support in next generation sequencing reports of somatic cancer variants
Dienstmann, R., Dong, F., Borger, D., Dias-Santagata, D., Ellisen, L. W., Le, L. P., & Iafrate, A. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.021 · Cited by 89
“…or similar catalogs of genes for which mutations have been causally implicated in cancer (Lawrence et al., 2014), as well as the Catalog of Somatic Mutations in Cancer (COSMIC; http://cancer.sanger.ac.uk/cancer-genome/projects/cosmic/) and…”
BackgroundTranslational research in oncology—10 years of progress and future prospects
Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 99
Mareschal, S., Dubois, S., Viailly, P., Bertrand, P., Bohers, E., Maingonnat, C., Jaïs, J., Tesson, B., Ruminy, P., Peyrouze, P., et al. (2016) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22328 · Cited by 89
“dataset of approximately 400 DLBCL samples (Lawrence et al., 2014).”
BackgroundResultInfluentialExome-wide somatic mutation characterization of small bowel adenocarcinoma
Hänninen, U. A., Katainen, R., Tanskanen, T. J., Plaketti, R., Laine, R., Hamberg, J., Ristimaki, A. P., Pukkala, E., Taipale, M., Mecklin, J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007200 · Cited by 90
Zhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 98
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway
Lou, H., Villagran, G., Boland, J. F., Im, K. M., Polo, S., Zhou, W., Odey, U., Juárez-Torres, E., Medina-Martínez, I., Roman-Basaure, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1837 · Cited by 88
Zaidi, S. H. E., Harrison, T. A., Phipps, A. I., Steinfelder, R. S., Trinh, Q. M., Qu, C., Banbury, B. L., Georgeson, P., Grasso, C. S., Giannakis, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17386-z · Cited by 95
Self-citationIlluminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 87
Self-citationCheng, F., Hong, H., Yang, S., & Wei, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw051 · Cited by 99
Role of immunotherapy in Ewing sarcoma
Morales, E., Olson, M., Cardenas, F. I., Dahiya, S., Luetkens, T., & Atanackovic, D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000653 · Cited by 98
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
Lin, A.-P., Abbas, S., Kim, S.-W., Ortega, M., Bouamar, H., Escobedo, Y., Varadarajan, P., Qin, Y., Sudderth, J., Schulz, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8768 · Cited by 86
“…that rare somatic D2HGDH mutation is a pervasive event in cancer; as mutation frequency is not an absolute determining factor for their relevance 28 , we propose that the final determination as to whether D2HGDH variants contribute to cancer initiation and/or progression awaits the generation…”
Li, L., & Wang, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788224 · Cited by 86
Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses
Torrente, L., Sanchez, C., Moreno, R., Chowdhry, S., Cabello, P., Isono, K., Koseki, H., Honda, T., Hayes, J. D., Dinkova-Kostova, A. T., et al. (2017) · Oncogene · doi:10.1038/onc.2017.221 · Cited by 87
“Not surprisingly therefore, NRF2 is often constitutively activated in human tumours37,39, where it is associated with poor prognosis40–42.”
Genetics of melanoma progression: the rise and fall of cell senescence
Bennett, D. C. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12422 · Cited by 85
“Melanomas have a median of 13–17 mutations per Mbp of DNA, the highest frequency among 21 cancer types analyzed (Hodis et al., 2012; Lawrence et al., 2014; The Cancer Genome Atlas Network, 2015), even without considering rearrangements, copy number alterations, and epigenetic changes.”
BackgroundPassenger Hotspot Mutations in Cancer
Hess, J. M., Bernards, A., Kim, J., Miller, M. L., Taylor-Weiner, A. N., Haradhvala, N. J., Lawrence, M. S., & Getz, G. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.002 · Cited by 99
Self-citationBajikar, S. S., Wang, C.-C., Borten, M. A., Pereira, E. J., Atkins, K. A., & Janes, K. A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.10.027 · Cited by 85
“For heavily sequenced cancers such as breast cancer (Lawrence et al., 2014), there are ripe opportunities to place somatic variants in the larger context of cancer cell biology.”
BackgroundSomatic clonal evolution: A selection-centric perspective
Scott, J. G., & Marusyk, A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.006 · Cited by 92
Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces
Engin, H. B., Kreisberg, J. F., & Carter, H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152929 · Cited by 84
Nohata, N., Abba, M. C., & Gutkind, J. S. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.014 · Cited by 85
Concepcion, C. P., Ma, S., LaFave, L. M., Bhutkar, A. J., Liu, M., DeAngelo, L. P., Kim, J. Y., Priore, I. S. D., Schoenfeld, A. J., Miller, M., et al. (2022) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 84
Leveraging big data of immune checkpoint blockade response identifies novel potential targets
Barèche, Y., Kelly, D., Aghababazadeh, F. A., Nakano, M., Esfahani, P. N., Tkachuk, D., Mohammad, H., Samstein, R. M., Lee, C., Morris, L. G. T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.084 · Cited by 90
Jenkins, M. L., Ranga-Prasad, H., Parson, M. A., Harris, N. J., Rathinaswamy, M. K., & Burke, J. E. (2023) · Nature Communications · doi:10.1038/s41467-023-35789-6 · Cited by 93
Comprehensive molecular profiling of lung adenocarcinoma
Lander, E. S. (2014) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 84
Self-citationMorel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 89
Compromised BRCA1–PALB2 interaction is associated with breast cancer risk
Foo, T. K., Tischkowitz, M. D., Simhadri, S. R., Boshari, T., Zayed, N., Burke, K. A., Berman, S. H., Blecua, P., Riaz, N., Huo, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.46 · Cited by 96
Identification of and molecular basis for sirt6 loss-of-function point mutations in cancer
Kugel, S., Feldman, J. L., Klein, M. A., Silberman, D. M., Sebastián, C., Mermel, C., Dobersch, S., Clark, A. R., Getz, G., Denu, J. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.022 · Cited by 81
Araya, C. L., Cenik, C., Reuter, J., Kiss, G., Pande, V. S., Snyder, M. P., & Greenleaf, W. J. (2015) · Nature Genetics · doi:10.1038/ng.3471 · Cited by 89
Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
Zhang, X., Kim, S., Hundal, J., Herndon, J. M., Li, S., Petti, A. A., Soysal, S. D., Li, L., McLellan, M. D., Hoog, J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0264 · Cited by 102
Predicting mutational routes to new adaptive phenotypes
Lind, P. A., Libby, E., Herzog, J., & Rainey, P. B. (2019) · eLife · doi:10.7554/elife.38822 · Cited by 93
Chen, H., Zhang, Z., Jiang, S., Li, R., Li, W., Zhao, C., Hong, H., Huang, X., Li, H., & Bo, X. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz072 · Cited by 91
Systematic characterization of mutations altering protein degradation in human cancers
Tokheim, C., Wang, X., Timms, R. T., Zhang, B., Mena, E. L., Wang, B., Chen, C., Ge, J., Chu, J., Zhang, W., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.020 · Cited by 83
“, ‘‘PASS’’ in the ‘‘filter’’ column), except for the allowance of whole genome amplified samples in ovarian cancer and AML where the majority of tumor samples used a whole genome amplification step; 2) tumor samples which failed pathology review were excluded; 3) for statistical power reasons, we excluded hypermutated…”
BackgroundWeSME: uncovering mutual exclusivity of cancer drivers and beyond
Kim, Y.-A., Madan, S., & Przytycka, T. M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw242 · Cited by 90
“nein 2 Heavy Chain (DYNC2H1) – while its partner is a known cancer driver (TTN, ARID1A), (AKT1, TTN), (DYNC2H1, PIK3CA). Previous work suggested that TTN and DYNC2H1 are unlikely to be cancer drivers [24]. Yet, TTN has rather a large number of partners A. B.! 7 in the mutual exclusivity network, suggesting that patien…”
BackgroundPan, W., Zhou, L., Ge, M., Zhang, B., Yang, X., Xiong, X., Fu, G., Zhang, J., Nie, X., Li, H., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw056 · Cited by 86
Zhang, Y., Yang, L., Kucherlapati, M., Chen, F., Hadjipanayis, A., Pantazi, A., Bristow, C. A., Lee, E. A., Mahadeshwar, H. S., Tang, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.025 · Cited by 82
Cracking the context-specific PI3K signaling code
Madsen, R. R., & Vanhaesebroeck, B. (2020) · Science Signaling · doi:10.1126/scisignal.aay2940 · Cited by 82
Mutational Biases Drive Elevated Rates of Substitution at Regulatory Sites across Cancer Types
Kaiser, V. B., Taylor, M. S., & Semple, C. A. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006207 · Cited by 82
“We compiled a total of 9,958,580 somatic single base substitutions across 1,574 tumour samples from 11 different tumour types; consistent with previous studies [2,5], there was a high degree of variation in substitution rates amongst tumour types (Table 1).”
InfluentialFusco, N., Geyer, F. C., Filippo, M. R. D., Martelotto, L. G., Ng, C. K. Y., Piscuoglio, S., Guerini‐Rocco, E., Schultheis, A. M., Fuhrmann, L., Wang, L., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.134 · Cited by 88
Interpretation of cancer mutations using a multiscale map of protein systems
Zheng, F., Kelly, M. R., Ramms, D. J., Heintschel, M. L., Tao, K., Tutuncuoglu, B., Lee, J. J., Ono, K., Foussard, H., Chen, M., et al. (2021) · Science · doi:10.1126/science.abf3067 · Cited by 81
Cell type-specific properties and environment shape tissue specificity of cancer genes
Schaefer, M. H., & Serrano, L. (2016) · Scientific Reports · doi:10.1038/srep20707 · Cited by 100
Gañán‐Gómez, I., Yang, H., Ma, F., Bravo, G. M., Thongon, N., Marchica, V., Richard‐Carpentier, G., Chien, K. S., Manyam, G. C., Wang, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01696-4 · Cited by 87
Hiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
“Recent large-scale genomics analysis found that some cancer types exhibit very high frequencies of p53 mutation, including ovarian cancer (95%), lung squamous cell carcinoma (84%), head and neck cancer (67%), and esophageal adenocarcinoma (65%) (Lawrence et al., 2014).”
Clermont, P.-L., Sun, L., Crea, F., Thu, K. L., Zhang, A., Parolia, A., Lam, W. L., & Helgason, C. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.474 · Cited by 85
“The CBX2 mutation frequency is thus considered very low, as high-frequency mutations are typically described as being over 20% and intermediate frequency as being between 2 and 20% (Lawrence et al, 2014).”
BackgroundIntegrating cancer genomic data into electronic health records
Warner, J. L., Jain, S. K., & Levy, M. A. (2016) · Genome Medicine · doi:10.1186/s13073-016-0371-3 · Cited by 88
“It has become readily apparent that the majority of cancers have thousands, if not hundreds of thousands, of discrete mutations, most of which are nonfunctional and related to background mutations, genomic instability, or defects in the neoplastic DNA repair machinery [80 – 82].”
BackgroundRational optimization of a transcription factor activation domain inhibitor
Basu, S., Martínez-Cristóbal, P., Frigolé-Vivas, M., Pesarrodona, M., Lewis, M., Szulc, E., Bañuelos, C. A., Sánchez-Zarzalejo, C., Bielskutė, S., Zhu, J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01159-5 · Cited by 83
“The molecular basis of TF condensation has been dissected for a small number of TFs and, in all cases, substitutions of amino acids in the IDRs that altered phase separation also altered transcriptional activity 15,20–22 .”
InfluentialThe genomic landscape of phaeochromocytoma
Flynn, A., Benn, D. E., Clifton-Bligh, R. J., Robinson, B. G., Trainer, A. H., James, P. A., Hogg, A., Waldeck, K., George, J., Li, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4503 · Cited by 89
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.